<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28760">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732327</url>
  </required_header>
  <id_info>
    <org_study_id>CAZ-MD-13</org_study_id>
    <nct_id>NCT02732327</nct_id>
  </id_info>
  <brief_title>Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer</brief_title>
  <official_title>A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam
      (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or
      linezolid as empiric therapy in febrile neutropenic adults with cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No longer aligned with the revised clinical development plan and commercial strategy
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) in the Modified Intent-to-Treat (MITT) Analysis Set</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response at EOIV in the Microbiological MITT (mMITT)</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response at EOIV in the Clinically Evaluable (CE) Analysis Set</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response at Test of Cure (TOC) and Late-Follow-Up (LFU) in the MITT Analysis Set</measure>
    <time_frame>TOC: Days 21-28; LFU: Days 35-42</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response by Baseline Gram-negative Pathogen at EOIV, TOC, and LFU in the mMITT Analysis Set</measure>
    <time_frame>EOIV: Up to Day 14; TOC: Days 21-28; LFU: Days 35-42</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response by Baseline Gram-negative Pathogen at EOIV, TOC, and LFU in the CE Analysis Set</measure>
    <time_frame>EOIV: Up to Day 14; TOC: Days 21-28; LFU: Days 35-42</time_frame>
    <description>Favorable clinical response is defined as resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Microbiological Response by Baseline Gram-negative Pathogen at EOIV, TOC, and LFU in the mMITT Analysis Set</measure>
    <time_frame>EOIV: Up to Day 14; TOC: Days 21-28; LFU: Days 35-42</time_frame>
    <description>Favorable microbiological response is defined as eradication (pathogen absent in the source specimen) or presumed eradication (sustained resolution of all acute signs and symptoms of primary infection) of the original pathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Microbiological Response by Baseline Gram-negative Pathogen at EOIV, TOC, and LFU in the Microbiologically Evaluable (ME) Analysis Set</measure>
    <time_frame>EOIV: Up to Day 14; TOC: Days 21-28; LFU: Days 35-42</time_frame>
    <description>Favorable microbiological response is defined as eradication (pathogen absent in the source specimen) or presumed eradication (sustained resolution of all acute signs and symptoms of primary infection) of the original pathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Infection-related Mortality at TOC and LFU in the MITT Analysis Set</measure>
    <time_frame>TOC: Days 21-28; LFU: Days 35-42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Infection-related Mortality at TOC and LFU in the mMITT Analysis Set</measure>
    <time_frame>TOC: Days 21-28; LFU: Days 35-42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 30-Day All-Cause Mortality in the MITT Analysis Set</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 30-Day All-Cause Mortality in the mMITT Analysis Set</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Neoplasms</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>CAZ-AVI + Vancomycin or Linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAZ-AVI</intervention_name>
    <description>Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)</description>
    <arm_group_label>CAZ-AVI + Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>15 mg/kg</description>
    <arm_group_label>CAZ-AVI + Vancomycin or Linezolid</arm_group_label>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>600 mg</description>
    <arm_group_label>CAZ-AVI + Vancomycin or Linezolid</arm_group_label>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime</intervention_name>
    <description>2 g</description>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>1 g</description>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>4.5 g</description>
    <arm_group_label>Standard of Care+Vancomycin or Linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with neutropenic fever who have existing malignancy or have undergone
             hematopoietic stem cell transplantation

          -  Requires hospitalization for intravenous (IV) empiric antibiotic therapy

        Exclusion Criteria:

          -  Fungal or viral infection requiring additional therapy

          -  Known acute viral hepatitis

          -  Known to be human immunodeficiency virus (HIV) positive

          -  Expected requirement for hemodialysis while on study therapy

          -  Received &gt;24 hours of systemic antibacterial therapy within 72 hours of initiation of
             inpatient IV study drug

          -  Past or current history of epilepsy or seizure disorder

          -  Evidence of immediately life-threatening disease, progressively fatal disease, or
             life expectancy of 3 months or less.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
